Tuberculosis: The drug development pipeline at a glance

Tuberculosis is a major disease causing every year 1.8 million deaths worldwide and represents the leading cause of mortality resulting from a bacterial infection. Introduction in the 60's of first-line drug regimen resulted in the control of the disease and TB was perceived as defeating. Howev...

Full description

Saved in:
Bibliographic Details
Published in:European journal of medicinal chemistry 2012-05, Vol.51, p.1-16
Main Authors: Villemagne, Baptiste, Crauste, Céline, Flipo, Marion, Baulard, Alain R., Déprez, Benoit, Willand, Nicolas
Format: Article
Language:English
Subjects:
Animals
Antitubercular Agents - adverse effects
Antitubercular Agents - pharmacology
Antitubercular Agents - therapeutic use
Biological and medical sciences
Clinical Trials as Topic
Drug Discovery - methods
Drug discovery and drug development
Humans
Life Sciences
Medical sciences
Miscellaneous
Mycobacterium tuberculosis
New molecular entities
Pharmacology. Drug treatments
Tuberculosis - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tuberculosis is a major disease causing every year 1.8 million deaths worldwide and represents the leading cause of mortality resulting from a bacterial infection. Introduction in the 60's of first-line drug regimen resulted in the control of the disease and TB was perceived as defeating. However, since the progression of HIV leading to co-infection with AIDS and the emergence of drug resistant strains, the need of new anti-tuberculosis drugs was not overstated. However in the past 40 years any new molecule did succeed in reaching the market. Today, the pipeline of potential new treatments has been fulfilled with several compounds in clinical trials or preclinical development with promising activities against sensitive and resistant Mycobacterium tuberculosis strains. Compounds as gatifloxacin, moxifloxacin, metronidazole or linezolid already used against other bacterial infections are currently evaluated in clinical phases 2 or 3 for treating tuberculosis. In addition, analogues of known TB drugs (PA-824, OPC-67683, PNU-100480, AZD5847, SQ609, SQ109, DC-159a) and new chemical entities (TMC207, BTZ043, DNB1, BDM31343) are under development. In this review, we report the chemical synthesis, mode of action when known, in vitro and in vivo activities and clinical data of all current small molecules targeting tuberculosis. Small molecules in clinical trials or preclinical development to treat tuberculosis are reported in this review. [Display omitted] ► This review presents anti-tuberculosis compounds currently in clinical trials. ► Promising strategies in preclinical development are described. ► The chemical synthesis, target and mechanism of action are highlighted. ► Activities observed in preclinical and clinical studies are reported.
ISSN:0223-5234
1768-3254
DOI:10.1016/j.ejmech.2012.02.033